HRSV (B) Pre-fusion glycoprotein F0, His Tag (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
RSF-V52H8-50ug
$465.00
RSF-V52H8-500ug
$2885.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    Prefusion glycoprotein F0/pre-F protein (RSV)

  • Source

    HRSV (B) Pre-fusion glycoprotein F0, His Tag (RSF-V52H8) is expressed from human 293 cells (HEK293).

  • Molecular Characterization

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 57.5 kDa. The protein migrates as 60-65 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

    The protein is designed as a trimer.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 0.1 M Sodium citrate, 150 mM NaCl, pH5.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    Prefusion glycoprotein F0/pre-F protein (RSV) SDS-PAGE

    HRSV (B) Pre-fusion glycoprotein F0, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    Prefusion glycoprotein F0/pre-F protein (RSV) SEC-MALS

    The purity of HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) is more than 90% and the molecular weight of this protein is around 190-240 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) at 1 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) with a linear range of 0.008-0.25 μg/mL (QC tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized Recombinant Human Anti-RSV Antibody (AM14), Human IgG1 at 1 μg/mL (100 μL/well) can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with a linear range of 0.5-31 ng/mL (QC tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) at 1 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) with a linear range of 0.1-4 ng/mL (Routinely tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) ELISA

    Immobilized Nirsevimab, Human IgG1 kappa at 1 μg/mL (100 μL/well) can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with a linear range of 0.2-16 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     Prefusion glycoprotein F0/pre-F protein (RSV) SPR

    Anti-Fusion glycoprotein F0 Antibody, Mouse IgG2a (101F) captured on Protein G-Series S sensor chip can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with an affinity constant of 0.766 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) SPR

    Monoclonal Anti-HRSV-A F/Fusion glycoprotein F0 Antibody, Human IgG1 (D25) captured on Protein G-Series S sensor chip can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with an affinity constant of 0.792 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) SPR

    Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (4G2) captured on Protein G-Series S sensor chip can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with an affinity constant of 6.69 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) SPR

    Monoclonal Anti-RSV-Pre-F0 specific Antibody, Human IgG1 (12C6) (Cat. No. RS0-S286) captured on Protein G-Series S sensor chip can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with an affinity constant of 2.71 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  •  Prefusion glycoprotein F0/pre-F protein (RSV) SPR

    Monoclonal Anti-RSV-F0 broadly Antibody, Mouse IgG1 (3B4) captured on CM5 chip via anti-mouse antibodies surface can bind HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) with an affinity constant of 2.58 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

FAQ

  • Product

    What do “pre” and “post” refer to in the names of viral proteins?

    In virology, “pre” refers to the conformation of a viral surface glycoprotein before fusion with the host cell membrane, while “post” refers to the conformation after membrane fusion and entry into the host cell. Both are naturally occurring states in the viral life cycle. Because the “pre” conformation represents a critical stage before viral entry, antibodies designed against this state often exhibit stronger neutralizing activity and are therefore more effective in preventing infection.

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • FAQ
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland